{"disease":{"id":"high-grade-serous-adenocarcinoma-of-ovary","name":"high grade serous adenocarcinoma of ovary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06161272","title":"Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT05446298","title":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06063070","title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05858736","title":"Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"OncoC4, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}